Enovis Co. (NYSE:ENOV) Shares Acquired by MML Investors Services LLC

MML Investors Services LLC increased its position in shares of Enovis Co. (NYSE:ENOV) by 17.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 44,179 shares of the company’s stock after buying an additional 6,476 shares during the period. MML Investors Services LLC’s holdings in Enovis were worth $1,902,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Enovis by 44.0% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 9,033 shares of the company’s stock valued at $408,000 after buying an additional 2,761 shares during the last quarter. Tributary Capital Management LLC grew its holdings in Enovis by 20.9% during the 2nd quarter. Tributary Capital Management LLC now owns 409,190 shares of the company’s stock worth $18,495,000 after acquiring an additional 70,819 shares in the last quarter. Institute for Wealth Management LLC. bought a new stake in shares of Enovis in the 2nd quarter worth about $241,000. AMG National Trust Bank raised its stake in shares of Enovis by 70.4% in the 2nd quarter. AMG National Trust Bank now owns 27,808 shares of the company’s stock valued at $1,257,000 after purchasing an additional 11,486 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Enovis in the 2nd quarter valued at about $904,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

ENOV stock opened at $45.78 on Tuesday. The stock’s fifty day moving average is $44.38 and its two-hundred day moving average is $44.56. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -20.90 and a beta of 1.94. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same period in the previous year, the business posted $0.56 EPS. Enovis’s revenue was up 21.0% on a year-over-year basis. On average, research analysts predict that Enovis Co. will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research analyst reports. Evercore ISI reduced their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Finally, JMP Securities started coverage on shares of Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.